These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 33833066)
1. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4. Pham LV; Pedersen MS; Fahnøe U; Fernandez-Antunez C; Humes D; Schønning K; Ramirez S; Bukh J Gut; 2022 Mar; 71(3):627-642. PubMed ID: 33833066 [TBL] [Abstract][Full Text] [Related]
2. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814 [TBL] [Abstract][Full Text] [Related]
3. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794 [TBL] [Abstract][Full Text] [Related]
4. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K; Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544 [TBL] [Abstract][Full Text] [Related]
6. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. Wang GP; Schnell GL; Kort JJ; Sidhu GS; Schuster L; Tripathi RL; Larsen L; Michael LC; Bergquist K; Magee A; Patel CB; Whitlock JA; Tamashiro R; Peter JA; Fried MW; Nelson DR J Hepatol; 2021 Oct; 75(4):820-828. PubMed ID: 34023351 [TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279 [TBL] [Abstract][Full Text] [Related]
8. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system. Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539 [TBL] [Abstract][Full Text] [Related]
9. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016 [TBL] [Abstract][Full Text] [Related]
10. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. Merli M; Rossotti R; Travi G; Ferla F; Lauterio A; Angelini Zucchetti T; Alcantarini C; Bargiacchi O; De Carlis L; Puoti M Transpl Infect Dis; 2019 Dec; 21(6):e13165. PubMed ID: 31487082 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Lok AS; Sulkowski MS; Kort JJ; Willner I; Reddy KR; Shiffman ML; Hassan MA; Pearlman BL; Hinestrosa F; Jacobson IM; Morelli G; Peter JA; Vainorius M; Michael LC; Fried MW; Wang GP; Lu W; Larsen L; Nelson DR Gastroenterology; 2019 Dec; 157(6):1506-1517.e1. PubMed ID: 31401140 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019. Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499 [TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea. Kim KA; Lee S; Park HJ; Jang ES; Lee YJ; Cho SB; Kim YS; Kim IH; Lee BS; Chung WJ; Ahn SH; Kim S; Jeong SH Clin Mol Hepatol; 2023 Apr; 29(2):496-509. PubMed ID: 36880209 [TBL] [Abstract][Full Text] [Related]
16. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. Ohya K; Imamura M; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Abe-Chayama H; Hayes CN; Aikata H; Ishida Y; Tateno C; Song H; Miyayama Y; Hijikata M; Chayama K Biochem Biophys Res Commun; 2021 Jun; 559():78-83. PubMed ID: 33932902 [TBL] [Abstract][Full Text] [Related]